Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

FHLC vs. RXL: which is better?

Bottom line

FHLC vs RXL: the short answer

FHLC (Fidelity MSCI Health Care Index ETF) and RXL (ProShares Ultra Health Care) share a meaningful slice of their top holdings — about 78% by weight.

But FHLC is far broader, holding 337 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.

FHLC is cheaper at 0.084% vs 0.95% — a difference of $87 a year per $10,000 invested.

Over five years, RXL returned +7.2% a year vs +7.2% for FHLC (reporting dates differ).

Updated Nov 19, 2026

FHLC vs RXL side by side

FHLCRXL
TypeETFETF
Fund familyFidelityProShares
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.084%0.95%
Annual cost per $10k$8.4$95
10-yr cost on $10k (prospectus)$108$1,305
Max front loadNoneNone
12b-1 fee0%—
1-yr return+2.6%+19.7%
5-yr return (annualized)+7.2%+7.2%
10-yr return (annualized)+8.8%+12.6%
Best quarter+16.4%+29.7%
Worst quarter−13.1%−28.9%
Net assets (fund)$3.3B$72.1M
Number of holdings33770
Portfolio turnover3%4%
Returns as ofNov 30, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearFHLCRXLDifference
2024+2.6%−2.7%+5.3%
2023+2.5%−3.2%+5.7%
2022−5.5%−15.1%+9.7%
2021+20.4%+47.8%−27.5%
2020+18.1%+19.2%−1.1%
2019+21.9%+38.9%−17.0%
2018+5.5%+5.4%+0.1%
2017+23.3%+46.0%−22.7%
2016−3.3%−8.9%+5.6%

Source: Fund prospectus bar charts

Holdings overlap

21 of FHLC's top 25 holdings also appear in RXL's top 25.

Shared top holdings
HoldingFHLCRXL
Eli Lilly & Co13.35%12.67%
Johnson & Johnson8.93%7.86%
AbbVie Inc6.42%5.57%
UnitedHealth Group Inc5.44%4.98%
Merck & Co Inc4.66%4.26%
Thermo Fisher Scientific Inc3.09%2.68%
Amgen Inc3.00%2.62%
Abbott Laboratories2.66%2.15%
Gilead Sciences Inc2.34%2.41%
Pfizer Inc2.06%2.15%
Bristol-Myers Squibb Co1.93%1.68%
CVS Health Corp1.92%1.67%
Intuitive Surgical Inc1.82%2.18%
Danaher Corp1.80%1.66%
Vertex Pharmaceuticals Inc1.76%1.64%

Source: SEC Form N-PORT

FHLC top 10

  1. Eli Lilly & Co — 13.35%
  2. Johnson & Johnson — 8.93%
  3. AbbVie Inc — 6.42%
  4. UnitedHealth Group Inc — 5.44%
  5. Merck & Co Inc — 4.66%
  6. Thermo Fisher Scientific Inc — 3.09%
  7. Amgen Inc — 3.00%
  8. Abbott Laboratories — 2.66%
  9. Gilead Sciences Inc — 2.34%
  10. Pfizer Inc — 2.06%

RXL top 10

  1. Eli Lilly & Co. — 12.67%
  2. ProShares GENIUS Money Market ETF — 11.81%
  3. Johnson & Johnson — 7.86%
  4. AbbVie, Inc. — 5.57%
  5. UnitedHealth Group, Inc. — 4.98%
  6. Merck & Co., Inc. — 4.26%
  7. Repurchase Agreement — 2.91%
  8. Thermo Fisher Scientific, Inc. — 2.68%
  9. Amgen, Inc. — 2.62%
  10. Gilead Sciences, Inc. — 2.41%

FAQ

What is the difference between FHLC and RXL?
FHLC (Fidelity MSCI Health Care Index ETF) and RXL (ProShares Ultra Health Care) share a meaningful slice of their top holdings — about 78% by weight. But FHLC is far broader, holding 337 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.
Which is cheaper, FHLC or RXL?
FHLC has the lower expense ratio (0.084%).
Should I own both FHLC and RXL?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.